Zheng Quan Zhi Xing·2025-05-12 08:41Core Viewpoint - The company has shown growth in revenue and profit for the fiscal year 2024, but faces challenges in its biopharmaceutical segment due to a competitive environment and high R&D costs [2][3]. Financial Performance - In 2024, the company achieved total revenue of 2.19 billion yuan, a 1.03% increase from 2.17 billion yuan in the previous year [2]. - Profit before tax reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [2]. - Net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% increase from 421.30 million yuan [2]. - In Q1 2025, the company reported a net profit of 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [2]. Biopharmaceutical Segment - The biopharmaceutical sector is a key part of the company's strategy but is currently facing a cooling market with high competition and investment risks [2][3]. - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [3]. Inventory and Sales Management - The company has improved its inventory management through a BI intelligent analysis system, achieving a healthier inventory cycle of 1.5 to 2 months [5]. - The company has implemented diverse promotional activities to stimulate end-market consumption and optimize inventory structure [5]. Product Development - The company is optimistic about the growth potential of its second and third-tier products, with specific products like the Guaifenesin capsule and the dizziness relief series expected to maintain or achieve significant growth [6]. Dividend Policy - The company has a consistent cash dividend policy, proposing a cash dividend of 0.35 yuan per share for 2024, totaling 206 million yuan [8]. - The company aims to maintain stable operating cash flow to support its dividend policy unless special funding needs arise [7]. Sales Expense Management - The company has been strict in controlling sales expenses, focusing on second and third-tier products while maintaining a balanced sales expense ratio [9].